文献速递免疫规划慢病防控与筛查卫生政策与健康促进

2007-2013年美国老年人带状疱疹疫苗覆盖率

Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007-2013.
PubMed 文献 · Am J Prev Med · 2016-10-26

本研究利用MarketScan数据库回顾性观察2007-2013年≥50岁参保人群带状疱疹疫苗覆盖率,并分析≥60岁成人接种相关因素。共纳入≥60岁成人6,746,476例和50-59岁成人6,770,294例。2013年50-59岁、60-64岁和≥65岁人群接种率分别为1.7%、23.9%和14.5%;≥65岁较60-64岁接种可能性更低(HR=0.543;95%CI=0.539,0.547)。结论估计≥60岁成人覆盖率19.5%,低于Healthy People 2020目标30%。

要点

  • 2013年带状疱疹疫苗接种率:50-59岁1.7%,60-64岁23.9%,≥65岁14.5%。
  • ≥65岁较60-64岁接种可能性更低,HR=0.543(95%CI=0.539,0.547)。
  • 接种流感疫苗者更可能接种带状疱疹疫苗,HR=1.841(95%CI=1.830,1.853)。

核心结论

  • 估计≥60岁成人带状疱疹疫苗覆盖率为19.5%,低于Healthy People 2020目标30%。
  • 作者认为提供者应识别每一次带状疱疹疫苗接种机会,以确保老年人免受带状疱疹这一疫苗可预防疾病的侵害。

研究设计与样本

  • 回顾性观察性研究,使用MarketScan数据库,于2015年开展。
  • 研究对象为2007-2013年≥60岁美国成人和2011-2013年50-59岁美国成人。
  • 共识别≥60岁成人6,746,476例和50-59岁成人6,770,294例。
  • 评估每个合格对象索引日期后的索赔记录以判定带状疱疹疫苗接种情况,并采用多因素分析探讨接种相关因素。

主要发现

  • 至2013年,50-59岁成人中1.7%、60-64岁成人中23.9%、≥65岁成人中14.5%接种了带状疱疹疫苗。
  • ≥65岁成人较60-64岁成人接种带状疱疹疫苗的可能性更低(HR=0.543;95%CI=0.539,0.547)。
  • 女性、免疫功能正常以及门诊医院、医生办公室和药房就诊次数更多的成人更可能接种带状疱疹疫苗。
  • 接种流感疫苗的成人更可能接种带状疱疹疫苗(HR=1.841;95%CI=1.830,1.853)。

临床怎么用

  • 作者认为提供者应识别每一次带状疱疹疫苗接种机会,以确保老年人免受带状疱疹这一疫苗可预防疾病的侵害。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to assess the coverage of herpes zoster (HZ) vaccine among a large cohort of insured individuals aged ≥50 years from 2007 to 2013, and to determine the factors associated with being vaccinated for adults aged ≥60 years. METHODS: This was a retrospective, observational study using the MarketScan® database conducted in 2015. The study population was U.S. adults aged ≥60 years during 2007-2013 and 50-59 years during 2011-2013. The claims of each eligible subject were evaluated post-index date to assess HZ vaccine uptake. Multivariate analyses were performed to understand factors associated with receiving HZ vaccine. RESULTS: A total of 6,746,476 adults aged ≥60 years and 6,770,294 adults aged 50-59 years were identified. By 2013, 1.7% of adults aged 50-59 years, 23.9% of adults aged 60-64 years, and 14.5% of adults aged ≥65 years received HZ vaccine. Adults aged ≥65 years were less likely to receive HZ vaccine than those aged 60-64 years (hazard ratio [HR]=0.543; 95% CI=0.539, 0.547). Adults who were female, immunocompetent, and had more outpatient hospital, doctor office, and pharmacy visits were more likely to receive HZ vaccine. Adults who received influenza vaccine were more likely to receive HZ vaccine (HR=1.841; 95% CI=1.830, 1.853). CONCLUSIONS: Estimated HZ vaccine coverage is 19.5% in adults aged ≥60 years, which is lower than the Healthy People 2020 target of 30%. Providers should identify every opportunity for HZ vaccination to assure that older adults are protected from HZ, a vaccine-preventable disease.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Zhang D, Johnson K, Newransky C, et al. Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007-2013. Am J Prev Med. 2016. PMID: 28340974. doi:10.1016/j.amepre.2016.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。